Literature DB >> 18191272

Potency of tenofovir in chronic hepatitis B: mono or combination therapy?

J G P Reijnders, H L A Janssen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18191272     DOI： 10.1016/j.jhep.2007.12.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  8 in total

1.  A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

Authors:  D Eldon Spackman; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Authors:  Vincent Soriano; Alan S Perelson; Fabien Zoulim
Journal:  J Antimicrob Chemother       Date:  2008-04-25       Impact factor: 5.790

Review 3.  Tenofovir disoproxil fumarate: in chronic hepatitis B.

Authors:  Caroline M Perry; Dene Simpson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

4.  The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.

Authors:  Mehlika Toy; Fatih Oguz Onder; Ramazan Idilman; Gokhan Kabacam; Jan Hendrik Richardus; Mithat Bozdayi; Meral Akdogan; Zarife Kuloglu; Aydan Kansu; Solko Schalm; Cihan Yurdaydin
Journal:  Eur J Health Econ       Date:  2012-07-20

Review 5.  Antiviral drugs for viruses other than human immunodeficiency virus.

Authors:  Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

6.  Tenofovir and its potential in the treatment of hepatitis B virus.

Authors:  Laura Reynaud; Maria Aurora Carleo; Maria Talamo; Guglielmo Borgia
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

7.  Hepatitis B virus infected health care workers in The Netherlands, 2000-2008.

Authors:  T J Daha; M A J Bilkert-Mooiman; C Ballemans; G Frijstein; J N Keeman; R A de Man; J E van Steenbergen; G Weers-Pothoff; H L Zaaijer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

8.  Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.

Authors:  Mehlika Toy; David W Hutton; Samuel K So
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.